A heart transplant center experience with basiliximab induction strategies: A double edged sword?

Luise Holzhauser Maxwell Norris Maria Molina Susan Chambers Swethika Sundaravel Eman Rashed Ketan Gala Tara Fallah Therese Bittermann Nosheen Reza Teresa S Wang Pavan Atluri Lee R Goldberg Rhondalyn McLean Eliot G Peyster

Published in: Clinical transplantation (2024)

Basiliximab reduces the incidence of ACR but increases the risk of AMR, CAV, and may be associated with increased mortality. Mechanistic studies are needed to describe a potential T-cell-escape mechanism with enhanced humoral immunity.

Keyphrases

risk factors
immune response
cardiovascular events
heart failure
case control
atrial fibrillation
type diabetes
risk assessment
climate change
antimicrobial resistance